IL6 and colorectal carcinoma: Hence, STAT3 inhibitor may not be the ideal therapeutic agent to treat mCRC because they cannot interrupt the interplay between HSCs and CRC cells which is mediated by VEGF and IL6 as demonstrated in our study.